Cargando…

In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis

Detalles Bibliográficos
Autor principal:	Lavie, Carl J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mayo Foundation for Medical Education and Research 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934692/ https://www.ncbi.nlm.nih.gov/pubmed/33958066 http://dx.doi.org/10.1016/j.mayocp.2021.03.002

Ejemplares similares

Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2021)

No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

In Reply — Cardiorespiratory Fitness Attenuates the Impact of Risk Factors Associated With COVID-19 Hospitalization
por: Lavie, Carl J., et al.
Publicado: (2021)

A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Reply to: ‘Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis’
por: Ji, Dong, et al.
Publicado: (2020)

Famotidine: A potential mitigator of mast cell activation in post-COVID-19 cognitive impairment
por: Kow, Chia Siang, et al.
Publicado: (2023)

Association of Obesity With More Critical Illness in COVID-19
por: Sharma, Abhishek, et al.
Publicado: (2020)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Authors’ Reply to Vrachatis et al. “Pharmaco-Immunomodulatory Therapy in COVID-19”
por: Rizk, John G., et al.
Publicado: (2020)

Re: ‘Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review - authors' reply’
por: Serafim, Rodrigo B., et al.
Publicado: (2021)

‘High prevalence of heterotopic ossification in critically ill patients with severe COVID-19’ – Author's reply
por: Stoira, Elisa, et al.
Publicado: (2021)

Famotidine Against SARS-CoV2: A Hope or Hype?
por: Ghosh, Ritwik, et al.
Publicado: (2020)

Author’s Reply: Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling All Asymptomatic Patients Before Surgical Treatment
por: Nahshon, Chen, et al.
Publicado: (2020)

Clinical course of severe and critically ill patients with coronavirus disease 2019 (COVID-19): A comparative study
por: Chen, Luyan, et al.
Publicado: (2020)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

Reply to: Covid-19: Involvement of the nervous system. Identifying neurological predictors defining the course of the disease
por: Mitchell, Nathan
Publicado: (2021)

Authors’ reply to the letter to editor “Acid suppressant use in association with incidence and severe outcomes of COVID‑19: a systematic review and meta‑analysis”
por: Kim, Hong-Bae, et al.
Publicado: (2022)

Reply: Multivitamin use may lower risk of preeclampsia: A meta‐analysis
por: Christiansen, Cecilie Holm, et al.
Publicado: (2022)

Reply - Letter to the Editor: Vitamin D deficiency in critically ill COVID-19 ARDS patients
por: Notz, Quirin, et al.
Publicado: (2022)

Definition and evolution of right ventricular dysfunction in critically ill COVID-19 patients. Author’s reply
por: Chew, Michelle S., et al.
Publicado: (2022)

Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
por: Chiu, Leonard, et al.
Publicado: (2021)

Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis
por: Sun, Chenyu, et al.
Publicado: (2021)

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis
por: Zhou, Yu-Jie, et al.
Publicado: (2020)

Reply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?
por: Slominski, Andrzej T., et al.
Publicado: (2020)

In Reply: Hormones and COVID-19
por: Park, Myung S., et al.
Publicado: (2023)

Reply to the letter of Singh and Singh in response to the article: “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis” (Kumar et al.)
por: Kumar, Ashish, et al.
Publicado: (2020)

Hormones and COVID-19
por: Elagizi, Andrew, et al.
Publicado: (2023)

A five-day course of ivermectin may reduce the duration of COVID-19 illness
por: Ahmed, Sabeena, et al.
Publicado: (2021)

Risk factors for severe COVID-19 illness in healthcare workers: Too many unknowns
por: Wander, Pandora L., et al.
Publicado: (2020)

Reply: The Impact of Acute Illness Severity on Post–COVID-19 Sequelae Remains an Unsettled Question
por: Townsend, Liam, et al.
Publicado: (2021)

In reply to: IL-6 serum level and olfactory dysfunction severity in COVID-19: correspondence
por: Vaira, Luigi Angelo, et al.
Publicado: (2022)

Reply to “In-Hospital Mortality Risk of Older Patients With COVID-19 Infection”
por: Covino, Marcello, et al.
Publicado: (2022)

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
por: Malone, Robert W., et al.
Publicado: (2020)

Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19
por: Alper, Kenneth
Publicado: (2020)

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
por: Malone, Robert W., et al.
Publicado: (2021)

Reply to “Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link”
por: Elgendy, Islam Y., et al.
Publicado: (2021)

Reply: Breast Implant Illness, Biofilm, and the Role of Capsulectomy
por: Lee, Mark A.
Publicado: (2020)

Efficacy of probiotics in the prevention of diarrhea in ventilated critically ill ICU patients: meta-analysis of randomized control trials: author’s reply
por: Batra, Priyam, et al.
Publicado: (2021)

Reply to: Letter to the Editor – N. Mitchell; Covid-19: Involvement of the nervous system. Identifying neurological predictors defining the course of the disease
por: Zifko, Udo, et al.
Publicado: (2021)

Reply to “The outbreak of COVID-19: An overview”
por: Wu, Yi-Chi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_btq16hbkv54tb775gn89t8f9bj